These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17201882)

  • 1. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments.
    González Carro P; Pérez Roldán F; De Pedro Esteban A; Legaz Huidobro ML; Soto Fernández S; Roncero Garcia Escribano O; Esteban López-Jamar JM; Pedraza Martin C; Ruíz Carrillo F
    J Gastroenterol Hepatol; 2007 Jan; 22(1):60-3. PubMed ID: 17201882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
    Borody TJ; Pang G; Wettstein AR; Clancy R; Herdman K; Surace R; Llorente R; Ng C
    Aliment Pharmacol Ther; 2006 Feb; 23(4):481-8. PubMed ID: 16441468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical Helicobacter pylori "rescue" therapy after failure of two eradication treatments.
    Gisbert JP; Gisbert JL; Marcos S; Pajares JM
    Dig Liver Dis; 2004 Jan; 36(1):7-12. PubMed ID: 14971810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
    Miehlke S; Hansky K; Schneider-Brachert W; Kirsch C; Morgner A; Madisch A; Kuhlisch E; Bästlein E; Jacobs E; Bayerdörffer E; Lehn N; Stolte M
    Aliment Pharmacol Ther; 2006 Jul; 24(2):395-403. PubMed ID: 16842467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin.
    Toracchio S; Capodicasa S; Soraja DB; Cellini L; Marzio L
    Dig Liver Dis; 2005 Jan; 37(1):33-8. PubMed ID: 15702857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
    Kim N; Park SH; Seo GS; Lee SW; Kim JW; Lee KJ; Shin WC; Kim TN; Park MI; Park JJ; Hong SJ; Shim KN; Kim SW; Shin YW; Chang YW; Chun HJ; Lee OJ; Jeon WJ; Park CG; Cho CM; Park CH; Won SY; Lee GH; Park KS; Shin JE; Kim HU; Park JY; Chae HS; Song GA; Kim JG; Yoon BC; Seol S; Jung HC; Chung IS
    Helicobacter; 2008 Dec; 13(6):542-9. PubMed ID: 19166420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
    Perri F; Festa V; Clemente R; Villani MR; Quitadamo M; Caruso N; Bergoli ML; Andriulli A
    Am J Gastroenterol; 2001 Jan; 96(1):58-62. PubMed ID: 11197288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.
    Ciccaglione AF; Tavani R; Grossi L; Cellini L; Manzoli L; Marzio L
    Helicobacter; 2016 Oct; 21(5):375-81. PubMed ID: 26807668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.
    Fiorini G; Vakil N; Zullo A; Saracino IM; Castelli V; Ricci C; Zaccaro C; Gatta L; Vaira D
    Clin Gastroenterol Hepatol; 2013 May; 11(5):507-10. PubMed ID: 23267869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.
    Navarro-Jarabo JM; Fernández N; Sousa FL; Cabrera E; Castro M; Ramírez LM; Rivera R; Ubiña E; Vera F; Méndez I; Rivas-Ruiz F; Moreno JL; Perea-Milla E
    BMC Gastroenterol; 2007 Jul; 7():31. PubMed ID: 17651479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
    Bosques-Padilla FJ; Garza-González E; Calderón-Lozano IE; Reed-SanRoman G; de Ariño Suárez M; Valdovinos-Díaz MA; Orozco-Gámiz A; Blancas-Valencia JM; Tamayo-de la Cuesta JL
    Helicobacter; 2004 Oct; 9(5):417-21. PubMed ID: 15361080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients.
    Pilotto A; Leandro G; Franceschi M; Bierti L; Di Battista R; Notarbartolo A; Pisciotta G; Grassi A; Crestani B; Tafner G; Michelagnoli S; Garotta F
    Hepatogastroenterology; 1999; 46(25):245-51. PubMed ID: 10228801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group.
    Adamek RJ; Bethke TD
    Am J Gastroenterol; 1998 Oct; 93(10):1919-24. PubMed ID: 9772056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.
    Sezgin O; Altintaş E; Uçbilek E; Tombak A; Tellioğlu B
    Helicobacter; 2007 Oct; 12(5):518-22. PubMed ID: 17760720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of clarithromycin-based triple therapy for treating Helicobacter pylori in Thai non-ulcer dyspeptic patients with clarithromycin-resistant strains.
    Mahachai V; Thong-Ngam D; Noophun P; Tumwasorn S; Kullavanijaya P
    J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S74-8. PubMed ID: 17718272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer].
    García-Romero E; del Val A; Garrigues V; Cuquerella J; Higón MD; Barrachina M; Pons V; Bixquert M; Ponce J
    Gastroenterol Hepatol; 1999 Jan; 22(1):1-6. PubMed ID: 10089703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing.
    Sivri B; Simsek I; Hulagu S; Kadayifci A; Tozun N; Akarsu M; Uraz S; Savas MC; Koruk M; Bozbas A
    Curr Med Res Opin; 2004 Aug; 20(8):1301-7. PubMed ID: 15324533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.